Abdulrahman Al Raizah: Mitapivat for Transfusion-Dependent Thalassemia – The ENERGIZE-T Phase 3 Trial
Abdulrahman Al Raizah, Mortality and Morbidity Meeting Lead, Adult Hematology Division at Ministry of National Guard Health Affairs (MNGHA), shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in The Lancet, adding:
“Just published in The Lancet, the ENERGIZE-T Phase 3 trial evaluated mitapivat in transfusion-dependent alpha and beta-thalassaemia, showing significant reductions in transfusion burden and cases of transfusion independence.
Following last year’s published ENERGIZE Phase 3 trial in non-transfusion-dependent thalassaemia, this second milestone underscores the clinical potential of oral pyruvate kinase activators across the full spectrum of thalassaemia management.
Participating in both the ENERGIZE trial last year and the ENERGIZE-T trial this year reflects the driving role of Ministry of National Guard Health Affairs (MNGHA) and King Abdullah International Medical Research Center (KAIMRC) in advancing global clinical research in hemoglobinopathies.
Sincere thanks to Prof Ahmed Alaskar and the entire KAIMRC team for their support—and above all, to the patients whose trust makes this work possible.
Privileged to have served as the site Principal Investigator for both trials.”
Title: Efficacy and safety of mitapivat in adults with transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE-T): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
Authors: Maria Domenica Cappellini, Sujit Sheth, Ali Taher, Hanny Al-Samkari, Ali Bülent Antmen, David Beneitez, Giovanna Cannas, Thomas Coates, Lauren Czapla, Jayme L Dahlin, Jeremie H Estepp, Elizabeth Feenstra, Pencho Georgiev, Sarah Gheuens, Gavrielle M Price, Andreas Glenthøj, Khaled M Musallam, Kareem Osman, John B Porter, Hui Shao, Katrin Uhlig, Eduard J van Beers, Vip Viprakasit, Kevin H M Kuo, Antonis Kattamis
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 28, 2026, 14:56Elizabeth Shirley: COVID-19 Vaccines, Spike Protein and Nitric Oxide Bioavailability
-
Oct 28, 2026, 14:39David Ledger: Anticoagulation Advances as Factor XIa Inhibition Reaches a New Milestone
-
Oct 28, 2026, 14:37Advancing Liver Health in Haemophilia Care – EAHAD
-
Oct 28, 2026, 14:34The Changing Landscape of Anticoagulant Therapy – ISTH
-
Oct 28, 2026, 14:17Clusterin Regulates von Willebrand Factor Multimer Stability Through ADAMTS13 Inhibition
-
Oct 28, 2026, 14:14Mina Jarrahi: Platelet-Rich Fibrin for Periodontal Regeneration
-
Oct 28, 2026, 14:06Mohammed Alo: A Stent Treats the Blockage, Not the Underlying Disease
-
Oct 28, 2026, 13:58Vladimir Lemaire: When Blood Clots Affect Elite Athletes
-
Oct 28, 2026, 13:27M. Alejandro Mosso-Pani: Dengue in Florida – Why Platelet Function Matters